Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study.

Vastert SJ, de Jager W, Noordman BJ, Holzinger D, Kuis W, Prakken BJ, Wulffraat NM.

Arthritis Rheumatol. 2014 Apr;66(4):1034-43. doi: 10.1002/art.38296.

2.

Anakinra in Systemic Juvenile Idiopathic Arthritis: A Single-center Experience.

Pardeo M, Pires Marafon D, Insalaco A, Bracaglia C, Nicolai R, Messia V, De Benedetti F.

J Rheumatol. 2015 Aug;42(8):1523-7. doi: 10.3899/jrheum.141567. Epub 2015 Jun 1.

PMID:
26034148
3.

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial).

Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, Bossuyt X, Boutten A, Bienvenu J, Duquesne A, Richer O, Chaussabel D, Mogenet A, Banchereau J, Treluyer JM, Landais P, Pascual V.

Ann Rheum Dis. 2011 May;70(5):747-54. doi: 10.1136/ard.2010.134254. Epub 2010 Dec 20.

4.

Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.

Otten MH, Prince FH, Armbrust W, ten Cate R, Hoppenreijs EP, Twilt M, Koopman-Keemink Y, Gorter SL, Dolman KM, Swart JF, van den Berg JM, Wulffraat NM, van Rossum MA, van Suijlekom-Smit LW.

JAMA. 2011 Dec 7;306(21):2340-7. doi: 10.1001/jama.2011.1671. Epub 2011 Nov 6.

PMID:
22056397
5.

Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients.

Romano M, Pontikaki I, Gattinara M, Ardoino I, Donati C, Boracchi P, Meroni PL, Gerloni V.

Reumatismo. 2014 Mar 17;65(6):278-85. doi: 10.4081/reumatismo.2013.682.

6.

Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.

Lequerré T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, Kone-Paut I, Michel M, Dernis E, Khellaf M, Limal N, Job-Deslandre C, Fautrel B, Le Loët X, Sibilia J; Société Francophone pour la Rhumatologie et les Maladies Inflammatoires en Pédiatrie (SOFREMIP); Club Rhumatismes et Inflammation (CRI).

Ann Rheum Dis. 2008 Mar;67(3):302-8. Epub 2007 Oct 18.

PMID:
17947302
7.

Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study.

Horneff G, Foeldvari I, Minden K, Trauzeddel R, Kümmerle-Deschner JB, Tenbrock K, Ganser G, Huppertz HI.

Arthritis Rheumatol. 2015 May;67(8):2240-9. doi: 10.1002/art.39145.

8.

The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis.

Gattorno M, Piccini A, Lasigliè D, Tassi S, Brisca G, Carta S, Delfino L, Ferlito F, Pelagatti MA, Caroli F, Buoncompagni A, Viola S, Loy A, Sironi M, Vecchi A, Ravelli A, Martini A, Rubartelli A.

Arthritis Rheum. 2008 May;58(5):1505-15. doi: 10.1002/art.23437.

9.

Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors.

Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O'Neil KM, Zeft AS, Szer IS, Ringold S, Brunner HI, Schanberg LE, Sundel RP, Milojevic DS, Punaro MG, Chira P, Gottlieb BS, Higgins GC, Ilowite NT, Kimura Y, Johnson A, Huang B, Lovell DJ; Childhood Arthritis and Rheumatology Research Alliance (CARRA).

J Rheumatol. 2014 Jun;41(6):1163-70. doi: 10.3899/jrheum.131503. Epub 2014 May 1.

PMID:
24786928
10.

A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.

Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R, Bader-Meunier B, Vastert SJ, Noseda E, D'Ambrosio D, Lecot J, Chakraborty A, Martini A, Chioato A; Paediatric Rheumatology International Clinical Trials Organisation.

Arthritis Rheum. 2012 Feb;64(2):557-67. doi: 10.1002/art.33342.

11.
12.

Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis.

DeWitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S, Schneider R, Stoll ML, Angeles-Han S, Milojevic D, Schikler KN, Vehe RK, Weiss JE, Weiss P, Ilowite NT, Wallace CA; Juvenile Idiopathic Arthritis Disease-specific Research Committee of Childhood Arthritis Rheumatology and Research Alliance.

Arthritis Care Res (Hoboken). 2012 Jul;64(7):1001-10. doi: 10.1002/acr.21625.

13.

Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.

Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G.

Arthritis Rheumatol. 2014 Sep;66(9):2580-9. doi: 10.1002/art.38741.

14.

Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.

Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP, van Santen-Hoeufft M, Koopman-Keemink Y, Wulffraat NM, van Suijlekom-Smit LW.

Ann Rheum Dis. 2009 May;68(5):635-41. doi: 10.1136/ard.2007.087411. Epub 2008 Apr 15.

PMID:
18413443
15.

Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis.

Lovell DJ, Giannini EH, Reiff AO, Kimura Y, Li S, Hashkes PJ, Wallace CA, Onel KB, Foell D, Wu R, Biedermann S, Hamilton JD, Radin AR.

Arthritis Rheum. 2013 Sep;65(9):2486-96. doi: 10.1002/art.38042.

16.

Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis.

Nordal E, Zak M, Aalto K, Berntson L, Fasth A, Herlin T, Lahdenne P, Nielsen S, Straume B, Rygg M; Nordic Study Group of Pediatric Rheumatology.

Arthritis Rheum. 2011 Sep;63(9):2809-18. doi: 10.1002/art.30426.

17.

Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.

Otten MH, Anink J, Prince FH, Twilt M, Vastert SJ, ten Cate R, Hoppenreijs EP, Armbrust W, Gorter SL, van Pelt PA, Kamphuis SS, Dolman KM, Swart JF, van den Berg JM, Koopman-Keemink Y, van Rossum MA, Wulffraat NM, van Suijlekom-Smit LW.

Ann Rheum Dis. 2015 Jul;74(7):1379-86. doi: 10.1136/annrheumdis-2013-204641. Epub 2014 Mar 18.

PMID:
24641940
18.

One-year followup study on clinical findings and changes in magnetic resonance imaging-based disease activity scores in juvenile idiopathic arthritis.

Hemke R, van Veenendaal M, van den Berg JM, Dolman KM, van Rossum MA, Maas M, Kuijpers TW.

J Rheumatol. 2014 Jan;41(1):119-27. doi: 10.3899/jrheum.130235. Epub 2013 Dec 1.

PMID:
24293575
19.

The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort.

Guzman J, Oen K, Tucker LB, Huber AM, Shiff N, Boire G, Scuccimarri R, Berard R, Tse SM, Morishita K, Stringer E, Johnson N, Levy DM, Duffy KW, Cabral DA, Rosenberg AM, Larché M, Dancey P, Petty RE, Laxer RM, Silverman E, Miettunen P, Chetaille AL, Haddad E, Houghton K, Spiegel L, Turvey SE, Schmeling H, Lang B, Ellsworth J, Ramsey S, Bruns A, Campillo S, Benseler S, Chédeville G, Schneider R, Yeung R, Duffy CM; ReACCh-Out investigators.

Ann Rheum Dis. 2015 Oct;74(10):1854-60. doi: 10.1136/annrheumdis-2014-205372. Epub 2014 May 19.

PMID:
24842571
20.

Anakinra for systemic juvenile arthritis: the Rocky Mountain experience.

Zeft A, Hollister R, LaFleur B, Sampath P, Soep J, McNally B, Kunkel G, Schlesinger M, Bohnsack J.

J Clin Rheumatol. 2009 Jun;15(4):161-4. doi: 10.1097/RHU.0b013e3181a4f459.

PMID:
19363453
Items per page

Supplemental Content

Write to the Help Desk